|
NJ Chapter Event:
Navigating the Funding Landscape: Insights for Early-Stage Biotechs
Thursday, May 18, 2023
5:30pm - 8:30pm
Basking Ridge Country Club
185 Madisonville Rd.
Basking Ridge, NJ 07920 
Program:
Join us for an engaging and timely event on May 18 at the Basking Ridge Country Club. Discover what it takes for early-stage biotechs to secure funding in today's challenging market conditions. This event will shed light on the unique challenges and opportunities facing the industry through in-depth case studies, insightful discussions, and a comprehensive analysis of current funding trends. Don't miss out on this invaluable opportunity to gain a competitive edge in the world of pharma deals. Register now and be a part of the conversation!
Panelists:
|
Pankaj Mohan, Ph.D., Founder, CEO & Chairman Dr. Pankaj Mohan founded Sonnet in 2015 and currently serves as Chief Executive Officer and Chairman. He is also a member of the Board of Directors of Outlook Therapeutics, Inc. which he also founded (formerly known as Oncobiologics). From January 2011 to June 2018, he served as Oncobiologics’ President, Chief Executive Officer, and Chairman. Previously, Dr. Mohan served as head of Business Operations and Portfolio Management of Biologics Process and Product Development at Bristol-Myers Squibb Company and as a Director of Bioprocess Engineering at Genentech, Inc. Prior to that Dr. Mohan served as a senior manager at Eli Lilly and Company. From May 1993 to April 1996, Dr. Mohan served as Assistant Professor (Lecturer/Fellow) at the Advanced Centre for Biochemical Engineering, University College London, London, United Kingdom. Dr. Mohan received a Doctor of Philosophy in Biochemical Engineering from the School of Chemical Engineering, University of Birmingham, Birmingham, United Kingdom, a master’s in financial management from Middlesex University Business School, London, United Kingdom, and a bachelor’s degree in chemical engineering from the Indian Institute of Technology in Roorkee, India. Dr. Mohan also attended an Executive Management Program (AMP) from Fuqua School of Business at Duke University. |
|
Sam Kongsamut, Ph.D., Co-founder, VP of R&D and Director of Briologyx
Dr. Kongsamut is current co-founder, VP of R&D and Director of Briologyx. He is a neuropharmacologist with over 25 years industry experience in small and large biopharma companies. He is currently engaged in various aspects of open innovation working with small and large organizations, mentoring, consulting, and working to build a life sciences entrepreneurial ecosystem. Sam obtained his PhD at the University of Chicago and had postdoctoral training at Cornell and Yale Universities. He then joined the pharmaceutical industry, working for a succession of five different companies (Hoechst-Roussel Pharmaceuticals Inc, Hoechst Marion Roussel, Aventis, Sanofi-Aventis. now Sanofi), and experiencing two mergers, one takeover, and one “transformation” without moving. Sam has managed various-sized groups of scientists in biochemical pharmacology that served multiple project teams in the neuroscience area, and was a member of the CNS Board that managed the CNS project portfolio. He led or worked on a variety of drug discovery and development projects covering a range of neuroscience areas (OCD, anxiety-depression, schizophrenia, Alzheimer’s Disease, Parkinson’s Disease, sleep disorders, multiple sclerosis, spinal cord injury, stroke), helping to translate animal pharmacology to human pharmacology, including being involved with two drugs that are now on the market. Sam was Director of External Innovation at Sanofi-Aventis, using his experience to identify opportunities for collaboration and licensing for broad therapeutic interests within the Neuroscience and Aging Units. Since leaving Sanofi in 2012, Sam founded Rudder Serendip LLC (steering from the rear close to the data towards serendipity), a consulting firm that serves clients at universities, foundations and biotechnology companies with advice on R&D plans and business development. Additionally, he has founded a company, worked for a small (7 pp) virtual biotech, and is deeply engaged with the local, national and international entrepreneurial community
|
 | Fred Callori, EVP, Corporate Development, Xontogeny Fred Callori serves as EVP, Corporate Development and started at Xontogeny in September 2017 as SVP, Corporate Development. Fred’s responsibilities include due diligence, deal structuring and negotiation, company formation, and the operational oversight and management of Xontogeny’s seed investments. He provides corporate governance, transactional and strategic advice to Xontogeny’s portfolio of companies and serves on several portfolio company boards. In 2018, Fred joined the Perceptive Xontogeny Venture Fund to help manage and oversee fund investments in portfolio companies, including continued investments in companies seeded and incubated at Xontogeny. Prior to joining Xontogeny, Fred was a Partner in the Life Science and Emerging Companies practices of Choate, Hall & Stewart LLP, a Boston law firm ranked among the most active firms worldwide for private equity and venture capital deals. During his 20-year tenure at Choate, Fred developed deep expertise in the formation, structure, financing and overall corporate development of early stage and emerging life science companies, including representing leading venture capital and institutional investment firms focused on investing in the sector. | 
| Akan Oton, Managing Director, Barings Akan Oton is a member of Barings’ Capital Solutions team and leads the
team’s investment strategy in healthcare. Akan joined the firm in 2017
and has worked in the industry since 1998, bringing over 24 years of
experience. At the firm, Akan has led the growth of the team’s
investment capabilities in pharmaceutical royalties and non-dilutive
healthcare finance. Akan currently sits on the board of Validus
Pharmaceuticals. Prior to joining the firm, Akan worked at Sandoz (a
division of Novartis), where he was an Executive Director and
responsible for product acquisition, licensing and led M&A
initiatives in generics and specialty brand segments. Prior to Sandoz,
Akan worked at Catalent Pharma Solutions, where he was responsible for
product partnering and technology licensing for the company’s venture
group. He has also held marketing leadership roles at both Cardinal
Health and Johnson & Johnson. Akan holds a B.S. in Mechanical
Engineering from Columbia University, an M.S. in Mechanical Engineering
from Massachusetts Institute of Technology, where he was a National
Science Foundation Graduate Fellow, and an M.B.A. from The Wharton
School at the University of Pennsylvania. He is also a Certified
Licensing Professional and a board member of the NJ Chapter of the
Licensing Executive Society.
|
Cost includes heavy appetizers, dessert, coffee, tea and soft drinks. A cash bar will be available. Click here to see the menu
| Member |
Non-Member
|
$85.00
| $95.00
|
Thank you to our partners:
 
Email Consent: By registering for this event, you permit LES to use your email address to communicate with you regarding LES events and their other services. You will have the ability to unsubscribe from these communications going forward.
|
Print Page
